Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 2
1953 3
1954 3
1956 2
1959 1
1961 16
1962 18
1963 19
1964 22
1965 23
1966 13
1967 32
1968 27
1969 32
1970 39
1971 40
1972 36
1973 29
1974 48
1975 30
1976 32
1977 53
1978 50
1979 51
1980 57
1981 66
1982 65
1983 74
1984 86
1985 116
1986 123
1987 120
1988 150
1989 155
1990 148
1991 138
1992 152
1993 162
1994 177
1995 176
1996 167
1997 204
1998 227
1999 186
2000 243
2001 247
2002 208
2003 253
2004 233
2005 246
2006 231
2007 271
2008 266
2009 247
2010 312
2011 305
2012 297
2013 285
2014 295
2015 288
2016 301
2017 315
2018 325
2019 299
2020 368
2021 462
2022 466
2023 361
2024 291

Text availability

Article attribute

Article type

Publication date

Search Results

9,949 results

Results by year

Filters applied: . Clear all
Page 1
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.
Nilsson MB, Yang Y, Heeke S, Patel SA, Poteete A, Udagawa H, Elamin YY, Moran CA, Kashima Y, Arumugam T, Yu X, Ren X, Diao L, Shen L, Wang Q, Zhang M, Robichaux JP, Shi C, Pfeil AN, Tran H, Gibbons DL, Bock J, Wang J, Minna JD, Kobayashi SS, Le X, Heymach JV. Nilsson MB, et al. Among authors: kobayashi ss. Cancer Cell. 2023 Feb 13;41(2):340-355.e6. doi: 10.1016/j.ccell.2023.01.007. Cancer Cell. 2023. PMID: 36787696 Free PMC article.
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T, Todaka A, Yanagimoto H, Morinaga S, Kobayashi S, Shimada K, Takahashi Y, Nakagohri T, Gotoh K, Kamata K, Shimizu Y, Ueno M, Ishii H, Okusaka T, Furuse J; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Nakachi K, et al. Among authors: kobayashi s. Lancet. 2023 Jan 21;401(10372):195-203. doi: 10.1016/S0140-6736(22)02038-4. Lancet. 2023. PMID: 36681415 Clinical Trial.
Periportal macrophages protect against commensal-driven liver inflammation.
Miyamoto Y, Kikuta J, Matsui T, Hasegawa T, Fujii K, Okuzaki D, Liu YC, Yoshioka T, Seno S, Motooka D, Uchida Y, Yamashita E, Kobayashi S, Eguchi H, Morii E, Tryggvason K, Shichita T, Kayama H, Atarashi K, Kunisawa J, Honda K, Takeda K, Ishii M. Miyamoto Y, et al. Among authors: kobayashi s. Nature. 2024 May;629(8013):901-909. doi: 10.1038/s41586-024-07372-6. Epub 2024 Apr 24. Nature. 2024. PMID: 38658756
Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH-HCC Guidelines).
Hasegawa K, Takemura N, Yamashita T, Watadani T, Kaibori M, Kubo S, Shimada M, Nagano H, Hatano E, Aikata H, Iijima H, Ueshima K, Ohkawa K, Genda T, Tsuchiya K, Torimura T, Ikeda M, Furuse J, Akahane M, Kobayashi S, Sakurai H, Takeda A, Murakami T, Motosugi U, Matsuyama Y, Kudo M, Tateishi R; committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma, Tokyo, Japan. Hasegawa K, et al. Among authors: kobayashi s. Hepatol Res. 2023 May;53(5):383-390. doi: 10.1111/hepr.13892. Epub 2023 Mar 10. Hepatol Res. 2023. PMID: 36826411
HSP47 levels determine the degree of body adiposity.
Shin J, Toyoda S, Okuno Y, Hayashi R, Nishitani S, Onodera T, Sakamoto H, Ito S, Kobayashi S, Nagao H, Kita S, Otsuki M, Fukuhara A, Nagata K, Shimomura I. Shin J, et al. Among authors: kobayashi s. Nat Commun. 2023 Nov 11;14(1):7319. doi: 10.1038/s41467-023-43080-x. Nat Commun. 2023. PMID: 37951979 Free PMC article.
Intravenous immunoglobulin for the treatment of Kawasaki disease.
Broderick C, Kobayashi S, Suto M, Ito S, Kobayashi T. Broderick C, et al. Among authors: kobayashi s. Cochrane Database Syst Rev. 2023 Jan 25;1(1):CD014884. doi: 10.1002/14651858.CD014884.pub2. Cochrane Database Syst Rev. 2023. PMID: 36695415 Free PMC article. Review.
Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions.
Watabe T, Naka S, Tatsumi M, Kamiya T, Kimura T, Shintani Y, Abe K, Miyake T, Shimazu K, Kobayashi S, Kurokawa Y, Eguchi H, Doki Y, Inohara H, Kato H, Mori Y, Cardinale J, Giesel FL. Watabe T, et al. Among authors: kobayashi s. J Nucl Med. 2023 Aug;64(8):1225-1231. doi: 10.2967/jnumed.123.265486. Epub 2023 Jun 2. J Nucl Med. 2023. PMID: 37268427 Free PMC article.
Mechanisms of action and resistance in histone methylation-targeted therapy.
Yamagishi M, Kuze Y, Kobayashi S, Nakashima M, Morishima S, Kawamata T, Makiyama J, Suzuki K, Seki M, Abe K, Imamura K, Watanabe E, Tsuchiya K, Yasumatsu I, Takayama G, Hizukuri Y, Ito K, Taira Y, Nannya Y, Tojo A, Watanabe T, Tsutsumi S, Suzuki Y, Uchimaru K. Yamagishi M, et al. Among authors: kobayashi s. Nature. 2024 Mar;627(8002):221-228. doi: 10.1038/s41586-024-07103-x. Epub 2024 Feb 21. Nature. 2024. PMID: 38383791 Free PMC article.
EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates.
Sentana-Lledo D, Academia E, Viray H, Rangachari D, Kobayashi SS, VanderLaan PA, Costa DB. Sentana-Lledo D, et al. Among authors: kobayashi ss. Transl Lung Cancer Res. 2023 Jul 31;12(7):1590-1610. doi: 10.21037/tlcr-23-98. Epub 2023 Jul 5. Transl Lung Cancer Res. 2023. PMID: 37577308 Free PMC article. Review.
9,949 results